# T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC

> **NCT00609219** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** autologous EBV specific CTLs

## Key facts

- **NCT ID:** NCT00609219
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2007-10
- **Final completion:** 2012-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609219, "T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00609219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*